is a first line treatment for patients with EGFR mutation for 1 locally advanced or metastatic,
Uses: effective in esophageal cancer patients whose tumours harboured additional copies of the EGFR gene. there is potential for its use in the treatment of other cancers where EGFR overexpression is involved. Erlotinib is another EGFR tyrosine kinase inhibitor that has a similar mechanism of action to gefitinib.
Tablets
10600 EGP
is a first line treatment for patients with EGFR mutation for 1 locally advanced or metastatic,
Uses: effective in esophageal cancer patients whose tumours harboured additional copies of the EGFR gene. there is potential for its use in the treatment of other cancers where EGFR overexpression is involved. Erlotinib is another EGFR tyrosine kinase inhibitor that has a similar mechanism of action to gefitinib.
Note: All the provided information about this drug does not substitute for consulting a doctor.